Media OutReach
CK Life Sciences Files Patent Applications for Circular mRNA TROP2 Cancer Vaccine
Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth Inhibition
HONG KONG SAR – Media OutReach Newswire – 11 April 2025 – CK Life Sciences Int’l., (Holdings) Inc. (“CK Life Sciences”), a leader in cancer vaccine development, announces the latest progress in its pharmaceutical R&D, namely the filing of an Original Grant Patent application in Hong Kong and a provisional patent application in the United States for novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (“TROP2”).
TROP2 is a cell surface glycoprotein that is overexpressed in a wide range of cancers, including breast, lung, pancreatic, and colorectal cancers. This protein plays a critical role in cell proliferation, migration, and invasion, and its overexpression is frequently linked to aggressive tumor behavior and poor clinical outcomes. Given its high expression in cancer cells and minimal presence in normal tissues, TROP2 has emerged as a promising therapeutic target in oncology.
TROP2-positive triple-negative breast cancer animal study demonstrated 100% tumor growth inhibition
TROP2 cancer vaccines covered by the patent application include innovative circular mRNA (circRNA) and fusion protein vaccine constructs that can induce robust T cell immune responses and have demonstrated impressive tumor growth inhibition in preclinical studies of triple-negative breast cancer and colorectal cancer. The results of animal studies involving triple-negative breast cancer (“TNBC”) have been encouraging, with mouse models showing 100% tumor growth inhibition after receiving the TROP2 cancer vaccine. Overall, 100% inhibition of tumor growth was achieved in four of the five studies when mice were treated with a TROP2 vaccine candidate, while the remaining study demonstrated approximately 80% tumor growth inhibition.
Triple-negative breast cancer disproportionately prevalent and aggressive among Asian women
The results of animal studies of the TROP2 cancer vaccines are of particular relevance to the Asian region. Breast cancer rates in Asia are rising sharply, with younger women widely affected. In particular, TNBC shows both higher prevalence and more aggressive behavior in Asian populations compared to Western counterparts. Additionally, TNBC has fewer treatment options and demonstrates significantly higher rates of metastasis and recurrence than other breast cancer subtypes.
Unprecedented anti-cancer efficacy
“TROP2 is an exciting therapeutic target and preclinical studies of our cancer vaccine in triple-negative breast cancer exhibited 100% inhibition of tumor growth, demonstrating unprecedented anti-cancer efficacy. We look forward to advancing our TROP2 cancer vaccine expeditiously into clinical trials to benefit patients and believe it holds significant potential in preventing cancer recurrence,” said Dr. Melvin Toh, Chief Scientific Officer at CK Life Sciences.
Data on the TROP2 cancer vaccines will be presented at upcoming cancer conferences. In recent years, CK Life Sciences has showcased its growing early-stage cancer vaccine pipeline through preclinical data presentations at leading oncology conferences, alongside the filing of multiple patents. Developed in its Hong Kong-based R&D laboratories, these innovative vaccines target a broad spectrum of tumor antigens, immune checkpoint proteins, and other key components within the tumor-immune microenvironment.
Hashtag: #CKLifeSciences #CancerVaccines #R&D #BreastCancer #PatentApplication #Pharmaceutical
The issuer is solely responsible for the content of this announcement.
About CK Life Sciences
CK Life Sciences Int’l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences’ operations are focused on conducting research and development into cancer vaccines and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.
Media OutReach
Asia Coach Group Partners with Veteran Business Consultant Rick Tam to Launch “Business Breakthrough” Programme for Hong Kong SMEs
Challenging Business Environment Demands New Solutions
Hong Kong’s SMEs are facing unprecedented operational pressures. According to a survey by CPA Australia, 37% of small businesses in Hong Kong struggle to obtain external financing. Data from Airwallex further reveals that 96% of SMEs have experienced cash flow difficulties in the past year. With property asset values declining, banks’ insistence on property collateral for loans has left many enterprises in financial distress.
Responding to Market Needs with Systematic Business Upgrade Solutions
“Hong Kong has never lacked capital—what’s missing is the mechanism to connect businesses with it,” Rick Tam noted. The programme addresses common pain points faced by local SMEs, including declining profits, low business valuations, tight cash flow, and recruitment challenges. Built upon the four-pillar framework of “Commerce, Strategy, Breakthrough, and Structure,” the curriculum covers stabilising cash flow and enhancing financial flexibility, repositioning businesses and improving client quality, reshaping product value and expanding profit margins, as well as systematising operations and attracting investors. The programme commits to helping participants improve cash flow, increase business value, and strengthen their business models within 90 days.
Four Practical Tools for Immediate Application
Participants will acquire four core tools: the “Cash Flow Vortex System” for rapid assessment of financial status and establishing safety buffers; the “A.T.C. Client Leverage Ladder” for repositioning and enhancing client value; the “High-Value Breakthrough Method” for creating products with greater value and trust; and the “Marketing Triangle Matrix” for integrating human resources, client bases, and operational systems to plan business expansion. The programme adopts a six-step progressive model—from restructuring business models, improving profit margins, attracting capital injection, building high-performance teams, and systematising operations, to ultimately helping business owners reclaim their time and freedom.
Instructor Credentials
Programme instructor Rick Tam is a graduate of the University of Hong Kong’s Business School and currently serves as CEO of two family offices and chief consultant to several others. He holds the CFPCM Certified Financial Planner designation. Tam has founded more than nine brands spanning wealth management, securities, and food and beverage sectors, and has guided over 1,000 participants through business expansion.
As Hong Kong’s economy seeks transformation, channelling capital precisely into the real economy through the “Business Breakthrough” approach offers more than a lifeline for SMEs—it injects vital momentum into Hong Kong’s long-term economic development.
Hashtag: #RickTam #AsiaCoach
The issuer is solely responsible for the content of this announcement.
Media OutReach
Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer
Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.
The acquisition of the brands supports Zuellig Pharma’s strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.
Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
International Entertainment Corporation to Hold EGM on 26 February 2026 for Proposed Convertible Notes Issuance
DigiPlus Interactive Corp., named as one of the Fortune Southeast Asia 500, together with its subsidiaries, is an innovative digital entertainment group in the Philippines and is a leader in the casinos and gaming industry. On 17 November 2025, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company conditionally agreed to issue and the Subscriber conditionally agreed to subscribe for the Notes in two tranches with a maturity of five years and an interest rate of 3% per annum.
Upon full conversion of the Notes at the initial Conversion Price, a total of 1,600,000,000 Shares will be issued by the Company, representing approximately 53.89% of the issued share capital of the Company as enlarged by the issue and allotment of the Conversion Shares. As such, the Subscriber will be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code, unless the Whitewash Waiver is granted and approved.
The initial Conversion Price of HK$1.00 per Conversion Share represents a discount of approximately 3.85% to the closing price of HK$1.04 per Share as quoted on the Stock Exchange on the Latest Practicable Date (6 February 2026).
The board of Directors (the “Board“) believes that the Subscription would be beneficial to improving and strengthening the Group’s liquidity and financial position on a longer-term basis. In the event that the Subscriber converts part or the full amount of the Notes into the Conversion Shares, it will also broaden the shareholder and capital base of the Company. The Group intends to apply part of the net proceeds raised from the issuance of the Notes of approximately HK$489.22 million for the early repayment of the Promissory Notes and interest accrued thereon (the “PN Repayment“), and approximately HK$392.39 million to early repay the Secured Bank Borrowing to achieve immediate interest savings.
The remaining net proceeds will primarily be used for funding the Investment Commitment and attractive investment/business opportunity(ies); and as general working capital of the Group. The Investment Commitment is currently expected to include capital investments for acquisition of land for the expansion of the Group’s integrated resort in Manila City in the Philippines (the ”Hotel”) and the construction of additional hotel rooms, for provision of other amenities of the integrated resort, and for ongoing upgrades, refurbishments and renovations to the facilities and infrastructures of both the Hotel and the Group’s existing casino (the “Casino“).
The Independent Board Committee, which comprises all the independent non-executive Directors, is of the opinion that (i) the terms of the Subscription Agreement are on normal commercial terms, and the terms of the Subscription, the Whitewash Waiver and the Special Deal (the PN Repayment to the PN Holder) are fair and reasonable so far as the Independent Shareholders are concerned; and (ii) the Subscription, the Whitewash Waiver and the Special Deal are in the interests of the Company and the Shareholders as a whole and as far as the Independent Shareholders are concerned. It, therefore, recommends the Independent Shareholders to vote in favour of the relevant resolution(s) to be proposed at the EGM.
Hashtag: #InternationalEntertainmentCorporation
The issuer is solely responsible for the content of this announcement.
About International Entertainment Corporation (HKEX: 1009)
International Entertainment Corporation is an investment holding company. The Company and its subsidiaries are principally involved in hotel operations, operating the gaming business under provisional licence and leasing of gaming venues at the hotel complex of the Group in Metro Manila in the Republic of the Philippines to a tenant for authorized gaming operation and live poker events in Macau.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn







